The PE Ratio as of December 2024 (TTM) for Denali Therapeutics Inc. (DNLI) is -7.58

According to Denali Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.58. This represents a change of -12.48% compared to the average of -8.66 of the last 4 quarters.

Denali Therapeutics Inc. (DNLI) Historical PE Ratio (quarterly & annually)

How has DNLI PE Ratio performed in the past?

The mean historical PE Ratio of Denali Therapeutics Inc. over the last ten years is 1.04. The current -7.58 PE Ratio has changed -73172.56% with respect to the historical average. Over the past ten years (40 quarters), DNLI's PE Ratio was at its highest in in the December 2020 quarter at 10.27. The PE Ratio was at its lowest in in the June 2021 quarter at -39.19.

Denali Therapeutics Inc. (DNLI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Denali Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Denali Therapeutics Inc. (DNLI) Average PE Ratio

How has DNLI PE Ratio performed in the past?

The current PE Ratio of Denali Therapeutics Inc. (DNLI) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Denali Therapeutics Inc. (DNLI) PE Ratio vs. Peers

How is DNLI’s PE Ratio compared to its peers?

Denali Therapeutics Inc.’s PE Ratio is less than Homology Medicines, Inc. (-0.01), less than Stoke Therapeutics, Inc. (-6.05), less than Atreca, Inc. (-0.06), less than Black Diamond Therapeutics, Inc. (-1.69), less than 4D Molecular Therapeutics, Inc. (-2.25), greater than Ascendis Pharma A/S (-17.80), greater than Apellis Pharmaceuticals, Inc. (-16.51), greater than BeiGene, Ltd. (-22.35), greater than Akero Therapeutics, Inc. (-8.36), greater than Blueprint Medicines Corporation (-44.77), greater than Legend Biotech Corporation (-17.16), greater than Vaxcyte, Inc. (-20.93), less than Travere Therapeutics, Inc. (-3.79), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Avidity Biosciences, Inc. (-13.79), greater than Revolution Medicines, Inc. (-13.06), greater than Day One Biopharmaceuticals, Inc. (-14.52), greater than SpringWorks Therapeutics, Inc. (-9.94), less than Monte Rosa Therapeutics, Inc. (-4.84), less than Design Therapeutics, Inc. (-7.53), less than Werewolf Therapeutics, Inc. (-1.08), less than Ikena Oncology, Inc. (-1.24),

Build a custom stock screener for Denali Therapeutics Inc. (DNLI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Denali Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Denali Therapeutics Inc. (DNLI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Denali Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.